PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas. [electronic resource]
Producer: 20160104Description: 1020-6 p. digitalISSN:- 1532-1827
- Animals
- Antineoplastic Agents -- administration & dosage
- Biomarkers, Tumor -- genetics
- Cell Survival -- drug effects
- Class I Phosphatidylinositol 3-Kinases
- Cystadenocarcinoma, Serous -- drug therapy
- Female
- Gene Amplification
- Humans
- Mice
- Mutation
- Phosphatidylinositol 3-Kinases -- genetics
- Receptor, ErbB-2 -- genetics
- Trastuzumab -- administration & dosage
- Uterine Neoplasms -- drug therapy
- Xenograft Model Antitumor Assays
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.